Home » Topics » BioWorld Science

BioWorld Science
RSS

YAP/TEAD expression defines distinct vulnerabilities in binary pan-cancer groups

Aug. 19, 2021

ExeVir's COVID-19 treatment and prophylactic XVR-011 enters clinical study

Aug. 18, 2021

Pirfenidone shows favorable effects in patients with HFpEF

Aug. 18, 2021

HER2 expression is a prognostic factor in DCIS

Aug. 18, 2021

Ganaxolone reduces seizure frequency in tuberous sclerosis complex patients

Aug. 18, 2021

Preclinical toxicology study supports development of antidiarrheal lechlemer

Aug. 18, 2021

Phase I study of Alzheimer's disease candidate AL-001 to begin in September

Aug. 18, 2021

Transcenta begins phase II trial of TST-001 in solid tumors

Aug. 18, 2021

Istari Oncology expands LUMINOS-103 trial of PVSRIPO to include HNSCC

Aug. 18, 2021

Sirnaomics describes new siRNAs targeting SARS-CoV-2

Aug. 18, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...